OSE Immunotherapeutics SA (EPA:OSE)
France · Delayed Price · Currency is EUR 3.394
-0.024 (-0.70%)
Jun 23, 2026, 5:35 PM CET
OSE Immunotherapeutics Employees
OSE Immunotherapeutics had 64 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
64
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
€42,047
Profits / Employee
€588,891
Market Cap
79.83M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 64 | 0 | - |
| Dec 31, 2024 | 64 | 9 | 16.36% |
| Dec 31, 2023 | 55 | -12 | -17.91% |
| Dec 31, 2022 | 67 | 6 | 9.84% |
| Dec 31, 2021 | 61 | 10 | 19.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Innate Pharma | 164 |
| Transgene | 145 |
| Adocia | 73 |
| Sensorion | 63 |
| Fermentalg | 63 |
| MaaT Pharma | 59 |
| ABIONYX Pharma | 49 |
OSE Immunotherapeutics News
- 13 days ago - OSE Immunotherapeutics Transcript: Status update - Transcripts
- 20 days ago - OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document - GlobeNewsWire
- 26 days ago - OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing - GlobeNewsWire
- 4 weeks ago - OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer - GlobeNewsWire
- 7 weeks ago - OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position - GlobeNewsWire
- 7 weeks ago - OSE Immunotherapeutics Earnings release: H2 2025 - Filings
- 7 weeks ago - OSE Immunotherapeutics Annual report: H2 2025 - Filings
- 2 months ago - OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients - GlobeNewsWire